Background: Studies report inconsistent performance of fecal immunochemical tests (FITs) for colorectal cancer (CRC) and advanced adenomas.
C
olorectal cancer (CRC) is a leading cause of death among digestive diseases and the second leading cause of cancer-related death in the United States (1) . Despite the effectiveness and cost-effectiveness of screening (2) (3) (4) , only 60% to 65% of the eligible population is current with screening (5), a rate that has fallen short of the goal of 80% by 2018 (2, 5, 6 ). This reflects concerns over the best test and strategy for screening. Colonoscopy is the most frequently used screening test in the United States (5) , but several other countries use annual or biennial stool blood tests or a combination of stool testing and lower endoscopy (7, 8) .
Although studies have shown that guaiac-based fecal occult blood testing reduces CRC incidence and mortality (9 -13) , it has several shortcomings, including low single-application sensitivity for CRC, poor detection of advanced adenomas (those with a diameter ≥1 cm, villous histologic characteristics, or high-grade dysplasia), the need for dietary and medication restrictions, and the requirement for more than 1 specimen. Use of the fecal immunochemical test (FIT) for human globulin is more sensitive and specific than guaiacbased fecal occult blood testing for CRC and advanced adenomas and has higher rates of participation and acceptance (14 -16). However, studies evaluating FIT performance characteristics have shown inconsistent findings for CRC and advanced adenomas. A systematic review published in 2014 summarized performance characteristics for CRC (17) but not for advanced adenomas. The objectives of this systematic review and meta-analysis were to provide an updated summary of FIT performance for CRC, quantify FIT performance characteristics for advanced adenomas, and evaluate whether variation in reported performance characteristics among studies is a function of the threshold used to define a positive test result or the test brand.
Study Selection
Two authors independently screened all titles and potentially relevant abstracts and then full texts of potentially eligible articles. Prospective or retrospective observational studies that were published in English; evaluated FIT sensitivity and specificity in asymptomatic, average-risk adults; and used colonoscopy as the reference standard were eligible for inclusion. Data only in abstract form or gray literature were not eligible.
Data Extraction and Quality Assessment
Two reviewers reviewed descriptive and quantitative data from each study. Data extraction was done primarily by 1 author (R.N.G.) and was independently validated by 2 others (T.F.I. or T.W.E.). For each study, we extracted data on sample size, mean age, brands of FIT used, thresholds for positivity (expressed as micrograms of hemoglobin per gram of feces), numbers of participants with CRC and advanced adenomas, and performance characteristics for both. Raw data on CRC and advanced adenomas were extracted when available. When only computed data were available, raw data were calculated based on identified proportions. For articles with missing data, the corresponding authors were contacted. When more than 1 FIT cutoff or threshold was used, performance characteristics for commonly used thresholds were extracted. Two authors (among T.F.I., R.N.G., and T.W.E.) independently assessed study characteristics and evaluated study quality by using the revised version of the QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) tool (21) . Discrepancies between reviewers for study quality assessment were resolved by discussion. The authors did not grade the quality of their own studies.
Data Synthesis and Analysis
Sensitivity and specificity at 1 or more thresholds were reported for each study. We combined studies and report results for CRC and advanced adenomas, with studies grouped by threshold (<10, 10, >10 to <20, 20, and >20 μg/g). To assess statistical heterogeneity, we calculated the I 2 measure, which indicates the percentage of total variation across studies that is due to heterogeneity rather than chance (22) . For all summary-level estimates, we used a bivariate generalized linear mixed model to simultaneously estimate pooled measures of sensitivity and specificity separately for CRC and advanced adenomas while accounting for the potential correlation between sensitivity and specificity. The bivariate approach provides unbiased estimates of sensitivity, specificity, and their correlation (23) and does not rely on an ad hoc continuity correction for zero marginal counts. Likelihood ratios were calculated using the bivariate estimates; positive likelihood ratios were calculated as sensitivity divided by (1 Ϫ specificity), and negative likelihood ratios were calculated as (1 Ϫ sensitivity) divided by specificity. Summary receiver-operating characteristic curves were obtained along with 95% confidence regions for the bivariate estimates of sensitivity and (1 Ϫ specificity). We also combined studies by FIT brand and by threshold to enable indirect comparisons.
Meta-DiSc software (Hospital Universitario Ramó n y Cajal) (24) was used to calculate the I 2 measure. For all other summary estimates of performance characteristics, the glmer function (25) of the lme4 package (26) in R (R Foundation for Statistical Computing) (27) was used to estimate the bivariate generalized mixed models (details are provided in the Supplement, available at Annals.org). 
Role of the Funding Source
The study was funded by the Department of Medicine and the Melvin and Bren Simon Cancer Center at the Indiana University School of Medicine and by the Regenstrief Institute. The funding sources had no role in the conception, design, or conduct of the study; analysis of the data; review of the manuscript; or the decision to submit it for publication.
RESULTS
Our search strategy (Appendix Table 1 ) generated 4976 citations, among which 31 articles were included in the analysis (Figure 1 ; Appendix Table 2 , available at Annals.org) (28 -58) . Studies were published between 2001 and 2018. Funding sources were not reported for 10 studies and included federal government (n = 15), private or intramural (n = 4), and corporate (n = 2) sources for the other studies. The total number of participants was 120 255, and sample sizes ranged from 284 to 21 805. Mean age ranged from 48.2 to 64 years. All study populations comprised asymptomatic, mostly average-risk persons in the screening age range (generally 50 to 75 years) who enrolled in screening colonoscopy programs for cancer prevention. Persons with prior colorectal neoplasia, inflammatory bowel disease, high-risk family history, or colonoscopy in the previous 5 to 10 years were excluded, as were (post hoc) those with inadequate bowel preparation or incomplete colonoscopy.
Eighteen FITs were tested, with individual studies testing 1 to 6 FITs. OC-Sensor (Eiken Chemical) was tested in 14 (58%) studies (35, 39 -42, 46 -49, 51, 52, 54, 56, 57), including OC FIT-CHEK (Eiken Chemical) in 2 (48, 57) of those 14 studies, OC-Light (Eiken Chemical) in 5 studies (29, 36, 37, 43, 45), and OC-Hemodia (Eiken Chemical) and FOB Gold (Sentinel Diagnostics) in 3 studies each (28, 30, 32, 33, 55, 58) . Many of the remaining FITs are or were available only in a single country or region. Thresholds for positivity ranged from 2 to 67 μg/g, with 11 studies using a positivity threshold of less than 10 μg/g, 17 using a threshold of 10 μg/g, 9 using a threshold of 11 to 19 μg/g, and 26 using a threshold of 20 μg/g or greater.
Performance characteristics of FITs for CRC and advanced adenomas based on each threshold tested for individual studies are shown in Appendix Table 2 . All studies assessed the sensitivity and specificity of 1 or more FITs for advanced adenomas, which ranged in prevalence from 1.26% to 12.2%, and all but 3 studies (33, 39, 51) did so for CRC, which ranged in prevalence from 0.15% to 3.48%.
We judged the quality of most studies as high (Appendix Figure 1 , available at Annals.org). All were cross-sectional. Only 1 had a prospective case-control design (46); for this study, we used data only from the control group, which, as in the other studies, comprised persons having screening colonoscopy. A lack of detail in study methods for nearly half the studies precluded us from knowing whether a consecutive or random sample of persons participated. Despite this, we assessed most studies as having low to moderate risk of selection bias. For approximately 30% of the studies, it was unclear whether FIT results and colonoscopic findings were interpreted independently. In 25% of the studies, the interval between the FIT and colonoscopy was not specified.
The studies tested 1 or more FITs; several used more than 1 threshold with the objective of determining the optimal one. The FIT was done before colonoscopy in all but 1 study (49), which provided no information. Although 5 studies did not explicitly state that the FIT results were interpreted without knowledge of the colonoscopic findings (28, 33, 39, 49, 56) , FIT processing was automated, making it unlikely that interpretation was biased by the findings. Colonoscopy was the reference standard in all studies. In 20 (65%) of 31 articles (29, 31, 33-38, 41-48, 50, 51, 54, 58), authors reported that colonoscopy was performed with blinding to the FIT results, whereas 11 articles (28, 30, 32, 39, 40, 49, 52, 53, 55-57) did not comment on blinding. Overall, we assessed risk of bias in interpretation of colonoscopic findings due to FIT results to be low. Several studies had post hoc exclusion of participants for various reasons, including not undergoing colonoscopy or completing FIT, inadequate bowel preparation, or incomplete colonoscopy (Appendix Table 3 , available at Annals.org). Only 3 studies provided information on indeterminate FITs, and only 1 of these studies made it clear that test results were truly indeterminate (Appendix Table 3 ). The number of participants excluded be- cause of an unsatisfactory colonoscopy was provided in nearly half the studies and ranged from 0.12% to 8.9%. The risk for biased patient flow affecting validity of FIT performance characteristics was assessed to be low (Appendix Figure 1 ).
Overall Performance Characteristics
I 2 values for heterogeneity were low to high for sensitivity and were high for specificity for all FIT thresholds for both CRC and advanced adenomas (Appendix Table 4 , available at Annals.org). Results were generated using a bivariate model. Error bars indicate 95% CIs. CRC = colorectal cancer; FIT = fecal immunochemical test. Results were generated using a bivariate model. Error bars indicate 95% CIs. CRC = colorectal cancer; FIT = fecal immunochemical test. Results were generated using a bivariate model. Error bars indicate 95% CIs. CRC = colorectal cancer; FIT = fecal immunochemical test. . OCLight's positive and negative likelihood ratios for CRC were 10.13 and 0.11, respectively. Aggregate point estimates for OC-Hemodia, based on 1 or 2 studies, were less robust ( Figure 6 ). For the remaining FITs, performance characteristics by threshold are shown in Figure 7 . For thresholds of 10, 11 to 19, and 20 μg/g, the Table shows comparisons of performance characteristics for 5 FIT brands, 3 of which are based on 1 or 2 studies. The most robust data at all 3 thresholds were for OC-Sensor. At a threshold of 10 μg/g, sensitivity for CRC and advanced adenomas was highest and overlapped among the 4 brands compared. Specificity at this cutoff for CRC and advanced adenomas was numerically highest for OC-Hemodia, with a 95% CI that overlapped only with OC-Light. At the threshold between 10 and 20 μg/g, there were large numerical differences in sensitivity for CRC (although with overlapping CIs) among OC-Sensor, OC-Hemodia, and FOB Gold, whereas specificity for CRC was nearly identical for OC-Sensor and FOB Gold (and both were higher than for OC-Hemodia). Differences in sensitivity for advanced adenomas among the 3 brands were smaller. At a threshold of 20 μg/g, sensitivity for CRC was numerically higher for FOB Gold, although CIs overlapped with those for OC-Sensor, and sensitivity for advanced adenomas was lower for OC-Hemodia. Specificity for advanced adenomas at this threshold was nearly identical among the 4 FITs. This analysis was limited by a small number of studies for some brands and a comparison that was based on different participants, which limits inferences about relative performance.
DISCUSSION
This systematic review and meta-analysis quantifies and compares FIT performance characteristics for CRC and advanced adenomas at 5 thresholds and, for 3 of them, compares performance characteristics among brands of FITs in 31 cross-sectional studies that had screening colonoscopy as the reference standard. We found that the positivity threshold has a greater effect on sensitivity and negative likelihood ratios than on specificity and positive likelihood ratios. At a threshold of 10 μg/g, sensitivity for CRC is as high as 0.91; specificity is 0.90; and positive and negative likelihood ratios are 9.19 and 0.10, respectively, magnitudes that are considered to have clinically important effects on diagnostic threshold (59)
Studies varied by sample size, country, population setting, age range, and FIT used (both the brand and its threshold), with several studies examining multiple thresholds. All study populations comprised asymptomatic and largely average-risk persons who had screening colonoscopy as part of a health promotion or disease prevention program on a local, regional, or national level. Prevalence of CRC and advanced adenomas varied among studies. This variation was likely related to the age of study participants and possibly the country or geographic region where the study was conducted. The extent to which study populations and disease prevalence affected findings is difficult to determine because FIT brands and thresholds also varied. At any threshold, 95% confidence limits overlapped for nearly all studies for both CRC and advanced adenomas, suggesting that positivity thresholds rather than disease prevalence were associated with individualstudy performance characteristics. Our quantitative results do not include a summary estimate of sensitivity and specificity from all studies and thresholds because this estimate would have limited clinical utility; although it might represent the "best" single estimate across all studies with their varying thresholds, it would not necessarily apply to a specific FIT at a specific threshold. Further, this analysis could not provide optimal test thresholds for CRC screening because this requires consideration of other factors, including colonoscopy resources available to investigate positive FIT results and the closely related false-positive rate. For CRC alone, the optimal threshold for a positive result might be between 10 and 20 μg/g (with a false-positive rate of 7%) or 20 μg/g or greater (with a false-positive rate of 5%), with the former increasing colonoscopy resources for false-positive results alone by 40%. Both thresholds have positive likelihood ratios greater than 10 and respective negative likelihood ratios of 0.20 and 0.30. For CRC and advanced adenomas, either of the same 2 thresholds would seem optimal, but the tradeoffs between them must be considered.
Our findings are consistent with those of 2 prior systematic reviews that informed our study methods (17, 18), 1 of which quantified performance characteristics for CRC only and included studies with the less accurate and potentially biased surrogate reference standard of 2-year follow-up without a CRC diagnosis (17) . The other review quantified performance characteristics for both CRC and advanced adenomas but included only studies of high-risk persons (18) . In addition, our searches identified a recent systematic review by Gies and colleagues that assessed 7 FIT brands across 22 studies (60). Although less comprehensive than ours, and despite inclusion of at least 1 study that contained persons with previous neoplasia (61), the researchers found areas under receiver-operating characteristic curves that were similar to our findings and determined that the high degree of heterogeneity reflected variation in test thresholds (60). Our findings are also consistent with a recent analysis by Selby and colleagues that considered repeated (that is, programmatic) testing with FIT, quantifying CRC detection at various thresholds (62). These investigators found that programmatic sensitivity was greater at lower thresholds but resulted in a higher number of positive results per cancer case detected.
This study has several limitations that require comment. Although we were able to assess several of the QUADAS-2 study quality criteria, for several studies a lack of detail in the methods prevented us from knowing whether a consecutive or random sample of persons participated, whether FIT results and colonoscopic findings were interpreted independently of one another, and the interval between FIT and colonoscopy. We did not include non-English-language studies, which could result in language bias, nor did we assess for publication bias. From a clinical perspective, these summary-level performance characteristics apply only to 1-time testing and not to serial testing, which is recommended in clinical practice. Further, we were unable to determine FIT performance characteristics for proximal and distal lesions separately. Zorzi and colleagues showed lower programmatic FIT-based screening for advanced neoplasia in the proximal colon, highlighting the need to understand the degree of differential FIT performance (63). Statistical heterogeneity was moderate or high for all analyses of specificity and for all analyses of sensitivity except for the 10 -μg/g threshold for CRC, for which heterogeneity was low. Given that the subgroup summary estimates showed performance characteristics that varied as expected on the basis of positivity threshold, the generally high degree of statistical heterogeneity of this systematic review was more likely due to the large sample sizes of the individual studies than to clinically important variation in study populations, particularly because the outcomes of CRC and advanced adenomas were common to all studies.
This systematic review suggests directions for future research on FITs, the most important of which is the need for a head-to-head comparison of different FITs at various thresholds for both CRC and advanced adenomas, with subgroups for proximal and distal lesions. Although such a study would be logistically challenging and would require a very large sample, it may be feasible within the framework of a regional or national screening colonoscopy program. The study would ensure use of the same stool sample and standardized preanalytic conditions. Other studies to consider include an analysis of programmatic performance characteristics based on the number of FIT rounds, as well as a quantitative analysis of the yield of FITs when combined with risk factors for advanced colorectal neoplasia to prioritize colonoscopy resources.
In conclusion, this systematic review provides new information about FIT performance characteristics for CRC and advanced adenomas as a function of test threshold. The findings suggest that FITs may be highly sensitive for CRC in a single application, though at the expense of a high false-positive rate. At high specificity, FITs are moderately sensitive for CRC. Although FITs are much less sensitive for advanced adenomas, the natural history of these lesions suggests annual transition rates to CRC of 3% to 6% (64), implying an opportunity for detection with programmatic screening. Health care systems need to consider the quantity and quality of data for a specific FIT, comparability of the population to the study populations for that particular FIT, and the clinical and economic effects of different test thresholds on colonoscopy and systems resources to optimize FITs for early detection and prevention of CRC. * 6 people in the ≤20-y age group and 3 in the ≥81-y age group. † Numbers of CRC cases and advanced adenomas calculated from percentages. ‡ Sponsor had no role in design, analysis, or manuscript preparation. § Study authors provided absolute numbers. ͉͉ OC FIT-CHEK was grouped with OC-Sensor in indirect comparative analyses. 
